#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	14768	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2045	715.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1453	1453	C	843	C	804	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3489	744.0	0	.	n	.	0	A20C	SNP	20	20	A	301	301	C	483	C,A	460,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3489	744.0	0	.	n	.	0	T695C	SNP	695	695	T	976	976	C	844	C,T	803,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3489	744.0	0	.	n	.	0	A1638G	SNP	1638	1638	A	1919	1919	G	851	G,A	811,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3489	744.0	0	.	n	.	0	T1971C	SNP	1971	1971	T	2252	2252	C	807	C	745	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3489	744.0	1	SNP	n	A2045G	0	.	.	2045	2045	A	2326	2326	A	814	A	770	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	26054	23S	2890	2890	99.86	23S.l15.c17.ctg.1	3489	744.0	1	SNP	n	C2597T	0	.	.	2597	2597	C	2878	2878	C	847	C	801	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2024	folP	855	855	100.0	folP.l15.c4.ctg.1	1524	132.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1013	1015	AGC	225;227;230	A;G;C	206;207;206	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5536	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3399	162.3	1	SNP	p	S91F	1	.	.	271	273	TTC	621	623	TTC	163;165;166	T;T;C	155;157;156	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5536	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3399	162.3	1	SNP	p	D95G	1	.	.	283	285	GGC	633	635	GGC	172;173;174	G;G;C	156;158;159	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5536	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3399	162.3	1	SNP	p	G95N	0	.	.	283	285	GGC	633	635	GGC	172;173;174	G;G;C	156;158;159	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1606	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1477	108.6	0	.	p	.	0	F184L	NONSYN	550	552	TTC	896	898	TTG	205;204;203	T;T;G	185;182;180	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	1606	mtrR	633	633	99.84	mtrR.l15.c17.ctg.1	1477	108.6	1	SNP	p	G45D	0	.	.	133	135	GGC	479	481	GGC	169;170;174	G;G;C,A	164;163;167,1	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	864	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c17.ctg.1	947	90.3	0	.	n	.	0	A197.	DEL	197	197	A	548	548	A	196	A	192	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5232	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3014	173.0	1	SNP	p	D86N	0	.	.	256	258	GAC	640	642	GAC	201;202;201	G;A;C	190;184;193	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5232	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3014	173.0	1	SNP	p	R87I	0	.	.	259	261	CGT	643	645	CGT	201;200;201	C,A;G;T	193,1;190;188	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5232	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3014	173.0	1	SNP	p	S87R	1	.	.	259	261	CGT	643	645	CGT	201;200;201	C,A;G;T	193,1;190;188	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5232	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3014	173.0	1	SNP	p	R87W	0	.	.	259	261	CGT	643	645	CGT	201;200;201	C,A;G;T	193,1;190;188	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5232	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3014	173.0	1	SNP	p	S88P	0	.	.	262	264	TCC	646	648	TCC	201;200;200	T;C;C	188;193;195	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4366	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2645	164.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1582	1584	GGC	232;236;239	G;G;C	213;215;213	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1355	1357	GCA	195;195;195	G;C,G;A	186;184,1;190	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1358	1360	ATC	199;204;206	A;T;C	194;198;200	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1370	1372	GTG	209;208;209	G;T;G	202;201;202	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1370	1372	GTG	209;208;209	G;T;G	202;201;202	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1874	1876	ACC	210;210;211	A;C,A;C	191;195,1;200	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1928	1930	GCG	189;192;190	G;C,G;G	170;157,1;168	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1928	1930	GCG	189;192;190	G;C,G;G	170;157,1;168	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2051	2053	AGC	158;161;161	A;G;C	152;154;154	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2060	2062	GGC	149;147;145	G;G;C	142;139;136	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	4018	penA	1752	1752	100.0	penA.l6.c30.ctg.1	2472	161.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2078	2080	CCG	137;139;138	C,G;C;GCCC,GGCCCC	98,1;101;93,1	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5688	ponA	2397	2397	99.92	ponA.l6.c30.ctg.1	3191	178.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2266	porA	1146	1146	99.83	porA.l15.c30.ctg.1	1971	114.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	620	620	C	140	C	128	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	0	.	p	.	0	N38E	NONSYN	112	114	AAT	498	500	GAA	251;246;247	G,A;A;A	237,1;232;236	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	0	.	p	.	0	P175S	NONSYN	523	525	CCA	909	911	TCA	227;225;223	T;C;A	215;214;212	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1038	1040	GTC	230;231;231	G;T,G;C	212;212,1;215	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1050	1052	TCT	228;223;223	T;C;T	213;211;211	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1368	1370	GCA	217;218;218	G;C;A	204;202;202	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	1	SNP	p	G120K	1	.	.	358	360	AAG	744	746	AAG	201;204;206	A;A;G	197;200;200	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	1	SNP	p	D121N	0	.	.	361	363	GAC	747	749	GAC	206;208;210	G;A;C,A	201;201;203,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2774	porB1b	1047	1047	99.24	porB1b.l15.c4.ctg.1	1576	174.4	1	SNP	p	A121D	1	.	.	361	363	GAC	747	749	GAC	206;208;210	G;A;C,A	201;201;203,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10406	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4849	214.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1172	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1128	103.3	1	SNP	p	V57M	1	.	.	169	171	ATG	504	506	ATG	229;227;227	A;T;G,A	215;216;212,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
